This ACE Clinical Guidance (ACG) covers clinical assessment, pharmacological treatment, and non-pharmacological strategies for managing asthma over the long term, with a focus on inhaled corticosteroid as the mainstay. The accompanying Appendix provides a list of preventer medications registered for asthma in Singapore.
Download the PDF below to access the ACG.
||Regularly assess asthma symptoms and risk of poor asthma outcomes, including factors that can influence these.
||Consider using a validated questionnaire to assess asthma symptoms.
||Assess factors influencing asthma symptoms or risk of poor asthma outcomes. These can be remembered with the acronym BREATHE.
||Use inhaled corticosteroid as the mainstay of long-term asthma management.
||For patients aged 6 years and older, do not use short-acting beta2 agonist alone (without a preventer) to treat asthma long term.
||Use a stepwise approach when selecting or adjusting preventer treatment for asthma (see Figure 2 on page 6).
||Educate all patients with asthma or their caregivers on how to self-manage.
||Regularly follow up all patients with asthma.
||Referral to a specialist could be made at any point.
Asthma and COVID-19
Local experts in Singapore have recently published a summary of international recommendations on asthma management during the COVID-19 pandemic, including use of spirometry, long-term asthma medications, and management of acute exacerbations.* Please note that recommendations in this area may change rapidly, corresponding to the evolution of evidence on COVID-19.
Find the article here.
* Ong KY, Tan TL, Chan AKW, et al. Managing asthma in the COVID-19 pandemic and current recommendations from professional bodies: a review. J Asthma. 2020. Doi: 10.1080/02770903.2020.1804578.